Payment overview · 2025
General Payments
$156.92
3 reported records · 2 companies
Healthcare provider profile · identity verified
Bridget Ross
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BAY CITY, MI · NPI 1982012308
Verified facts
What the public records show
CMS Open Payments records show Bridget Ross received $156.92 in general payments during 2025 across 3 reported records.
ABIOMED accounted for 66.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $104.95 | 66.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.97 | 33.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $156.92 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $51.97 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 57 |
| Omeprazole | Omeprazole | 329 | 53 |
| Simvastatin | Simvastatin | 269 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 50 |
| Lisinopril | Lisinopril | 202 | 43 |
| Furosemide | Furosemide | 168 | 35 |
| Potassium Chloride | Potassium Chloride | 168 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 30 |
| Famotidine | Famotidine | 121 | 24 |
| Buspirone Hcl | Buspirone Hcl | 117 | 20 |
| Metformin Hcl | Metformin Hcl | 116 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 39 |
| Gabapentin | Gabapentin | 97 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 25 |
| Levetiracetam | Levetiracetam | 90 | 18 |
| Sertraline Hcl | Sertraline Hcl | 88 | 23 |
| Eliquis | Apixaban | 85 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 23 |
| Trazodone Hcl | Trazodone Hcl | 83 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 16 |
| Losartan Potassium | Losartan Potassium | 79 | 23 |
| Calcitriol | Calcitriol | 78 | 15 |
| Carvedilol | Carvedilol | 76 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 75 | 13 |
| Allopurinol | Allopurinol | 70 | suppressed |
| Topiramate | Topiramate | 66 | suppressed |
| Nystatin | Nystatin | 65 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 12 |
| Risperidone | Risperidone | 63 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 60 | suppressed |
| Atenolol | Atenolol | 58 | suppressed |
| Lovastatin | Lovastatin | 58 | suppressed |
| Vascepa | Icosapent Ethyl | 57 | suppressed |
| Baclofen | Baclofen | 54 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Meloxicam | Meloxicam | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Niacin Er | Niacin | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Ozempic | Semaglutide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $156.92 · 3 records | ABIOMED | Xtandi | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error